FDA swiftly puts Makary era in the rearview mirrornews2026-07-22T19:02:19+00:00July 22nd, 2026|Endpoints News|
Former FDA cancer chief Pazdur says the agency should restructurenews2026-07-22T18:46:02+00:00July 22nd, 2026|Endpoints News|
FDA approves Nuvalent’s cancer drug, a week after GSK closed $10.6B buyoutnews2026-07-22T18:21:51+00:00July 22nd, 2026|Endpoints News|
Arrowhead’s gene silencer competitive with Ionis’ in triglyceride diseasenews2026-07-22T15:32:21+00:00July 22nd, 2026|Endpoints News|
Mentari adds $200M to migraine mission; Royalty’s latest ATTR-CM dealnews2026-07-22T14:17:01+00:00July 22nd, 2026|Endpoints News|
Q&A: Lilly returns to neuropsych and looks ahead to Alzheimer’s preventionnews2026-07-22T14:00:14+00:00July 22nd, 2026|Endpoints News|
Crystalys gets $130M to take Sobi-rivaling gout drug to marketnews2026-07-22T12:00:36+00:00July 22nd, 2026|Endpoints News|
Summit reports two-year survival data for Western patients, though context lackingnews2026-07-22T11:37:14+00:00July 22nd, 2026|Endpoints News|
Celldex scraps antibody in prurigo nodularis after Phase 2 flopnews2026-07-22T10:49:00+00:00July 22nd, 2026|Endpoints News|
Biopharma dealmaking in 2026: The recovery gathers speed in Q2news2026-07-22T10:45:36+00:00July 22nd, 2026|Endpoints News|